Abstract
Over 5 million new rectal cancer diagnoses are made globally per year. The mainstay of treatment is to offer a total mesorectal excision (TME) with or without concurrent neo-adjuvant chemo-radio-therapy, thereby offering a 63–64% overall survival at 5 years with complete (R0) resection [1]. This is true for rectal cancers in the absence of a threatened resection margin. However, 5–10% transgress the conventional resection margin (CRM) and invade adjacent structures at the time of diagnosis. In addition, despite high quality TME surgery in cases where tumour does not threaten the CRM, there is a 10% local recurrence rate.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
